These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7504239)

  • 41. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.
    Guillon C; Stankovic K; Ataman-Onal Y; Biron F; Verrier B
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1283-92. PubMed ID: 17209772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV regulatory proteins: potential targets for therapeutic intervention.
    Rosen CA
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):175-81. PubMed ID: 1540405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A tripartite HIV-1 tat-env-rev fusion protein.
    Salfeld J; Göttlinger HG; Sia RA; Park RE; Sodroski JG; Haseltine WA
    EMBO J; 1990 Mar; 9(3):965-70. PubMed ID: 2178928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory genes of human immunodeficiency viruses.
    Wong-Staal F; Haseltine WA
    Mol Genet Med; 1992; 2():189-219. PubMed ID: 1458225
    [No Abstract]   [Full Text] [Related]  

  • 45. Direct RNA binding by the rev product of HIV-1.
    Walley AJ; Heaphy S; Jones IM
    AIDS; 1989 Dec; 3(12):859-61. PubMed ID: 2517208
    [No Abstract]   [Full Text] [Related]  

  • 46. Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA.
    Unwalla H; Banerjea AC
    Biochem J; 2001 Jul; 357(Pt 1):147-55. PubMed ID: 11415445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins.
    Ulich C; Harrich D; Estes P; Gaynor RB
    J Virol; 1996 Jul; 70(7):4871-6. PubMed ID: 8676525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Splicing affects presentation of RNA dimerization signals in HIV-2 in vitro.
    Lanchy JM; Szafran QN; Lodmell JS
    Nucleic Acids Res; 2004; 32(15):4585-95. PubMed ID: 15333691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A docking and modelling strategy for peptide-RNA complexes: applications to BIV Tat-TAR and HIV Rev-RBE.
    Srinivasan J; Leclerc F; Xu W; Ellington AD; Cedergren R
    Fold Des; 1996; 1(6):463-72. PubMed ID: 9080192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance.
    Luukkonen BG; Tan W; Schwartz S
    J Virol; 1995 Jul; 69(7):4086-94. PubMed ID: 7769666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.
    Staffa A; Cochrane A
    Mol Cell Biol; 1995 Aug; 15(8):4597-605. PubMed ID: 7623851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Robust growth of human immunodeficiency virus type 1 (HIV-1).
    Kim H; Yin J
    Biophys J; 2005 Oct; 89(4):2210-21. PubMed ID: 16055539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes.
    Tornatore C; Meyers K; Atwood W; Conant K; Major E
    J Virol; 1994 Jan; 68(1):93-102. PubMed ID: 8254781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional classification of simian immunodeficiency virus isolated from a chimpanzee by transactivators.
    Sakuragi J; Sakai H; Sakuragi S; Shibata R; Wain-Hobson S; Hayami M; Adachi A
    Virology; 1992 Jul; 189(1):354-8. PubMed ID: 1604820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel glutamine-RNA interaction identified by screening libraries in mammalian cells.
    Tan R; Frankel AD
    Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4247-52. PubMed ID: 9539722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A structural model for the HIV-1 Rev-RRE complex deduced from altered-specificity rev variants isolated by a rapid genetic strategy.
    Jain C; Belasco JG
    Cell; 1996 Oct; 87(1):115-25. PubMed ID: 8858154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RNA binding assays for Tat-derived peptides: implications for specificity.
    Weeks KM; Crothers DM
    Biochemistry; 1992 Oct; 31(42):10281-7. PubMed ID: 1384694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro selection of ribozymes dependent on peptides for activity.
    Robertson MP; Knudsen SM; Ellington AD
    RNA; 2004 Jan; 10(1):114-27. PubMed ID: 14681590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Compatibility of Tat and Rev transactivators in the primate lentiviruses.
    Sakai H; Sakuragi J; Sakuragi S; Kawamura M; Adachi A
    Arch Virol; 1993; 129(1-4):1-10. PubMed ID: 8385908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Principles and applications of a Tat-based assay for analyzing specific RNA-protein interactions in mammalian cells.
    Cullen BR
    Methods Enzymol; 2000; 328():322-9. PubMed ID: 11075353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.